

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

INSIDE INFORMATION
ISSUANCE OF FILING NOTICE BY THE CSRC FOR
THE H SHARE FULL CIRCULATION AND
PROPOSED IMPLEMENTATION OF
H SHARE FULL CIRCULATION BY THE COMPANY

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated December 15, 2025 (the “**Announcement**”) in relation to the proposed implementation of H share full circulation program by the Company. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The Company has submitted an application to the CSRC on behalf of 23 shareholders of the Company (the “**Shareholders**”) in respect of the conversion of an aggregate of 44,391,598 Unlisted Shares held by such 23 Shareholders into the H Shares (the “**H Share Full Circulation**”). The Board is pleased to announce that on May 7, 2026, the Company received the “Notification of filing on the ‘Full Circulation’ of Unlisted Shares of Nanjing Leads Biolabs Co., Ltd.” (the “**Filing Notice**”) dated April 27, 2026 and issued by the CSRC regarding the H Share Full Circulation. Pursuant to the Filing Notice, if the Company fails to complete the Conversion and Listing within 12 months from the date of issuance of the Filing Notice, the Company shall update the filing materials if it intends to proceed with it.

On May 8, 2026, the Company has further submitted the filing materials with the CSRC in respect of the conversion of 1,221,511 Unlisted Shares held by one Shareholder into H shares. The Company will apply to the Stock Exchange for the Conversion and Listing, and the completion of the Conversion and Listing are subject to the completion of relevant procedures as required by the Stock Exchange and other relevant regulatory authorities. Pursuant to the articles of association of the Company, no further shareholders' meeting is required to be convened to approve the Conversion and Listing. The Company will make further announcement(s) on the progress of the H Share Full Circulation and the Conversion and Listing in compliance with the Listing Rules as and when appropriate.

The H Share Full Circulation and the Conversion and Listing are subject to other relevant procedures as required by the Stock Exchange and other domestic and overseas regulatory authorities. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
Chief Executive Officer*

Nanjing, PRC, May 8, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng and Dr. Chen Renhai as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive directors.